SKSaul J. Karpen

Saul J. Karpen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Saul J. Karpen has a total of 79 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • 502 - Natural History and Risk Factors for Variceal Hemorrhage in Biliary Atresia: Results of a Prospective Multi-Center Longitudinal Analysis

    by Lee Bass, Wen Ye, Kieran Hawthorne, Daniel H. Leung, Karen F. Murray, Jean P. Molleston, Rene Romero, Ronald J. Sokol, Saul J. Karpen, Philip Rosenthal, et al.


  • Mo1446 - Initial Results of the Wuppsc Study – Prospective Multicenter Withdrawal of Ursodeoxycholic Acid in Pediatric Primary Sclerosing Cholangitis (PSC)

    by Dennis D. Black, Cara L. Mack, Nanda Kerkar, Tamir Miloh, Shikha S. Sundaram, Ravinder Anand, Ashutosh Gupta, Estella Alonso, Ronen Arnon, Pinar Bulut, et al.


  • 372 Bile Acids Induce Myocardial Dysfunction: Candidate Mechanism for Cirrhotic Cardiomyopathy

    by Moreshwar Desai, Sayeepriyadarshini Anakk, Zeena Eblimit, Renan A. Orellana, Hernan G. Vasquez, Henry C. Wu, Heinrich Taegtmeyer, Daniel J. Penny, Saul J. Karpen, David D. Moore

  • Portal Hypertension in Children and Young Adults With Biliary Atresia

    by Benjamin L. Shneider, Bob Abel, Barbara Haber, Saul J. Karpen, John C. Magee, Rene Romero, Kathleen Schwarz, Lee M. Bass, Nanda Kerkar, Alexander G. Miethke, et al.

    Objective: Biliary atresia (BA) frequently results in portal hypertension (PHT), complications of which lead to significant morbidity and mortality. The Childhood Liver Disease Research and Education Network was used to perform a cross‐sectional multicentered analysis of PHT in children with BA.Methods: Subjects with BA receiving medical management at a Childhood Liver Disease Research and Education Network site were enrolled. A priori, clinically evident PHT was defined as “definite” when there was either history of a complication of PHT or clinical findings consistent with PHT (both splenomegaly and thrombocytopenia). PHT was denoted as “possible” if one of the findings was present in the absence of a complication, whereas PHT was “absent” if none of the criteria were met.Results: A total of 163 subjects were enrolled between May 2006 and December 2009. At baseline, definite PHT was present in 49%, possible in 17%, and absent in 34% of subjects. Demographics, growth, and anthropometrics were similar amongst the 3 PHT categories. Alanine aminotransferase, γ‐glutamyl transpeptidase, and sodium levels were similar, whereas there were significant differences in aspartate aminotransferase (AST), AST/alanine aminotransferase, albumin, total bilirubin, prothrombin time, white blood cell count, platelet count, and AST/platelet count between definite and absent PHT. Thirty‐four percent of those with definite PHT had either prothrombin time >15 seconds or albumin <3 g/dL.Conclusions: Clinically definable PHT is present in two‐thirds of North American long‐term BA survivors with their native livers. The presence of PHT is associated with measures of hepatic injury and dysfunction, although in this selected cohort, the degree of hepatic dysfunction is relatively mild and growth is preserved.


  • A Prospective Clinical Trial Shows That Intravenous N-Acetylcysteine (NAC) Does Not Improve Survival in Pediatric Patients With Non-Acetaminophen Acute Liver Failure

    by Robert Squires, Anil Dhawan, Estella M. Alonso, Michael R. Narkewicz, Norberto Rodriguez-Baez, Deirdre A. Kelly, John Bucuvalas, Saul J. Karpen, Benjamin L. Shneider, Elizabeth B. Rand, et al.


  • Open Access

    Hypertrophic Cardiomyopathy and Dysregulation of Cardiac Energetics in A Mouse Model of Biliary Fibrosis

    by Moreshwar S. Desai, Zainuer Shabier, Michael Taylor, Fong Lam, Sundararajah Thevananther, Astrid Kosters, Saul J. Karpen

    Cardiac dysfunction is a major cause of morbidity and mortality in patients with end-stage liver disease; yet the mechanisms remain largely unknown. We hypothesized that the complex interrelated impairments in cardiac structure and function secondary to progression of liver diseases involve alterations in signaling pathways engaged in cardiac energy metabolism and hypertrophy, augmented by direct effects of high circulating levels of bile acids. Biliary fibrosis was induced in male C57BL/6J mice by feeding a 0.1% 3,5-diethoxycarbonyl-1,4-dihydroxychollidine (DDC) supplemented diet. After 3 weeks, mice underwent live imaging (dual energy x-ray absorptiometry [DEXA] scanning, two-dimensional echocardiography [2DE], electrocardiography, cardiac magnetic resonance imaging), exercise treadmill testing, and histological and biochemical analyses of livers and hearts. Compared with chow-fed mice, DDC-fed mice fatigued earlier on the treadmill, with reduced VO2. Marked changes were identified electrophysiologically (bradycardia and prolonged QT interval) and functionally (hyperdynamic left ventricular [LV] contractility along with increased LV thickness). Hearts of DDC-fed mice showed hypertrophic signaling (activation of v-akt murine thymoma viral oncogene/protein kinase B [AKT], inhibition of glycogen synthase kinase-3β [GSK3β], a 20-fold up-regulation of β myosin heavy chain RNA and elevated Gsα/Giα ratio. Genes regulating cardiac fatty acid oxidation pathways were suppressed, along with a threefold increase in myocardial glycogen content. Treatment of mouse cardiomyocytes (which express the membrane bile acid receptor TGR5) with potent natural TGR5 agonists, taurochenodeoxycholic acid and lithocholic acid, activated AKT and inhibited GSK3β, similar to the changes seen in DDC-fed mouse hearts. This provides support for a novel mechanism whereby circulating natural bile acids can induce signaling pathways in heart associated with hypertrophy. Conclusion: Three weeks of DDC feeding-induced biliary fibrosis leads to multiple functional, metabolic, electrophysiological, and hypertrophic adaptations in the mouse heart, recapitulating some of the features of human cirrhotic cardiomyopathy. Hepatology 2010;51:2097–2107


  • The Role of Inflammation in Cholestasis: Clinical and Basic Aspects

    by Astrid Kosters, Saul Karpen

    Hepatobiliary transport systems are essential for the uptake and excretion of a variety of compounds including bile acids. Disruption and dysregulation of this excretory pathway result in cholestasis, leading to the intrahepatic accumulation of bile acids and other toxic compounds with progression of liver pathology. Cholestasis induced by inflammation is a common complication in patients with extrahepatic infections or inflammatory processes, generally referred to as sepsis-associated cholestasis. Microbial products, including endotoxin, induce signaling pathways within hepatocytes either directly, or through activation of proinflammatory cytokines, leading to rapid and profound reductions in bile flow. The expression and function of key hepatobiliary transporters are suppressed in response to inflammatory signaling. These proinflammatory signaling cascades lead to repressed expression and activity of a large number of nuclear transcriptional regulators, many of which are essential for maintenance of hepatobiliary transporter gene expression. Interestingly, recently discovered molecular crosstalk between bile acid activated nuclear receptors and proinflammatory nuclear mediators may provide new means of understanding adaptive processes within liver. Inflammation-induced cholestasis and the effects of retained molecules in cholestasis on inflammatory signals are interwoven in the liver, providing potential opportunities for research and therapeutics.


  • Bile acid transporters in health and disease

    by A. Kosters, S. J. Karpen

    In recent years the discovery of a number of major transporter proteins expressed in the liver and intestine specifically involved in bile acid transport has led to improved understanding of bile acid homeostasis and the enterohepatic circulation. Sodium (Na+)-dependent bile acid uptake from portal blood into the liver is mediated primarily by the Na+ taurocholate co-transporting polypeptide (NTCP), while secretion across the canalicular membrane into the bile is carried out by the bile salt export pump (BSEP). In the ileum, absorption of bile acids from the lumen into epithelial cells is mediated by the apical Na+ bile salt transporter (ASBT), whereas exit into portal blood across the basolateral membrane is mediated by the organic solute transporter α/β (OSTα/β) heterodimer. Regulation of transporter gene expression and function occurs at several different levels: in the nucleus, members of the nuclear receptor superfamily, regulated by bile acids and other ligands are primarily involved in controlling gene expression, while cell signalling events directly affect transporter function, and subcellular localization. Polymorphisms, dysfunction, and impaired adaptive responses of several of the bile acid transporters, e.g. BSEP and ASBT, results in liver and intestinal disease. Bile acid transporters are now understood to play central roles in driving bile flow, as well as adaptation to various pathological conditions, with complex regulation of activity and function in the nucleus, cytoplasm, and membrane.